Andrew C. Jackson, Chief Financial Officer at Calidi Biotherapeutics, Inc. (CLDI), bought 2,500 shares at $2.00 ($5K) on 2025-08-21, disclosed to the SEC on 2025-08-25.
Open-market purchase of $5k CLDI by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Clearly above the average filing.
| Filing → |
| RMED | BUY | 2020-05-27 | $5K | — | Filing → |
| RMED | SELL | 2019-06-17 | $16K | — | Filing → |